The present invention relates to methods of treating or preventing a metabolic disorder in a subject, methods of treating or preventing coronary artery disease in a subject with a metabolic disorder, as well as methods of reducing hepatic glucose production in a subject. Such methods include, but are not limited to, the administration to the subject of inhibitors or activators of CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1, Dach2, or any combination thereof. The invention also provides methods of identifying a compound that inhibits the activity of CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1 or Dach2, or reduces the activity and/or activation of CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1 or Dach, or activates CaMKII, IP3Rs, calcineurin, p38, MK2/3, HDAC4, Dach1 or Dach2.

Disclosed herein are methods, compositions, apparatus, systems and kits for performing polynucleotide amplification utilizing a pure polynucleotide polymerase. In some cases, disclosed herein are methods, compositions, apparatus, systems and kits for sequencing polynucleotides.

The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods and kits for determining the human sperm quality.

The present invention relates to a method of determining a metabolic adaptation of a living entity of interest to a first set of environmental conditions and to a second set of environmental conditions comprising (a) determining with a first substrate concentration at least two activities of at least one enzyme comprised in a specimen of said living entity maintained under said first set of environmental conditions and at least two activities of said at least one enzyme comprised in a specimen of said living entity maintained under said second set of environmental conditions, wherein said activities are determined at two non-identical points in time t.sub.1 and t.sub.2 after starting the determining reaction; (b) determining with a second substrate concentration at least two activities of at least one enzyme comprised in a specimen of said living entity maintained under said first set of environmental conditions and at least two activities of said at least one enzyme comprised in a specimen of said living entity maintained under said second set of environmental conditions, wherein said activities are determined at two non-identical points in time t.sub.3 and t.sub.4 after starting the determining reaction; wherein said second substrate concentration is at most twofold, preferably is about equal to or lower than, the K.sub.M of said enzyme for said substrate; and (c) determining the metabolic adaptation of said living entity based on comparing at least one non-linear activity determined in step (a) and/or (b) to at least one further activity determined in step (a) and/or (b). The present invention also relates to devices and further methods related thereto; as well as to a redox-fixed HMGB1 derivative polypeptide.

The present invention is directed toward novel methods to identify as well as to treat a subject having an inflammatory disease resistant to corticosteroids.

Therapeutic treatments of a tumor expressing pT346 PDK1, including glioma expressing pT346 PDK1, are disclosed.

Disclosed herein are methods of treating HIBM in a subject comprising identifying subject in need thereof; and administering to the subject a compound, or a pharmaceutically acceptable salt, ester, amide, glycol, peptidyl, or prodrug thereof, wherein the compound is a compound that is biosynthesized in a wild type individual along a biochemical pathway between glucose and sialic acid, inclusive. Also disclosed herein are vectors comprising a nucleic acid sequence that encodes a polypeptide having at least 80% sequence identity to the sequence set forth in SEQ ID NO:2, recombinant cells comprising these vectors, and recombinant animals comprising the cells. In addition, methods of identifying a compound having therapeutic effect for HIBM are disclosed.

The present invention relates to methods of using HEATR1 expression levels for guiding chemotherapy treatment of pancreatic cancer. In particular, measuring lower HEATR1 expression in pancreatic cancer is associated with resistance to the use of certain chemotherapy treatments such that by changing the treatment a better prognosis may be obtained for the patient. Further, lower HEATR1 expression is related to a poorer long-term prognosis of pancreatic cancer patients thus measuring an increase or maintenance/decrease during treatment may be useful for predicting treatment response.

The present invention is based, in part, on the identification of novel FI.3K-mTORCI-S6K 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.